Skip to main content
. 2019 May 13;76(8):906–914. doi: 10.1001/jamaneurol.2019.1120

Figure 2. Subgroup Analysis of Intracerebral Hemorrhage (Aspirin vs Placebo or No Aspirin).

Figure 2.

The sizes of the data markers indicate the weight of each trial. AAA indicates the Aspirin for Asymptomatic Atherosclerosis trial; APLASA, the Antiphospholipid Antibody Acetylsalicylic Acid study; ARRIVE, the Aspirin to Reduce Risk of Initial Vascular Events study; ASCEND, A Study of Cardiovascular Events in Diabetes; ASPREE, the Aspirin in Reducing Events in the Elderly trial; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); JPAD, the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes Trial; JPPP, the Japanese Primary Prevention Project; POPADAD, the Prevention of Progression of Arterial Disease and Diabetes trial; RR, relative risk; and WHS, the Women’s Health Study.